TherapeuticsMD
TXMD
41 hedge funds and large institutions have $3.03M invested in TherapeuticsMD in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
250% more call options, than puts
Call options by funds: $14K | Put options by funds: $4K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
11% more funds holding
Funds holding: 37 → 41 (+4)
1.3% more ownership
Funds ownership: 29.31% → 30.61% (+1.3%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
46% less capital invested
Capital invested by funds: $5.61M → $3.03M (-$2.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$205K |
| 2 |
Renaissance Technologies
New York
|
+$15.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.53K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$1.6K |
| 5 |
Morgan Stanley
New York
|
+$943 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
-$9.55K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.99K |
| 3 |
CC
Clearline Capital
New York
|
-$1.97K |
| 4 |
CPA
Capital Performance Advisors
Walnut Creek,
California
|
-$996 |
| 5 |
PS
Principal Securities
Des Moines,
Iowa
|
-$209 |
TXMD Hedge Fund Activity: Q4 2024 in Review
41 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2024, worth a combined $3.03M — down 46% from $5.61M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TXMD positions and 4 closed out — a net gain of 4 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $205K. The largest seller was Tejara Capital, cutting an estimated $9.55K.
- 41 institutional investors held TherapeuticsMD (TXMD) as of Q4 2024, up from 37 in Q3 2024.
- Funds reported $3.03M of TherapeuticsMD stock for Q4 2024, down 46% quarter-over-quarter.
- 8 funds opened new TherapeuticsMD positions in Q4 2024 and 4 closed out, a net change of +4 holders.
- The largest TherapeuticsMD buyer in Q4 2024 was Citadel Advisors, an estimated $205K added.
- The largest TherapeuticsMD seller in Q4 2024 was Tejara Capital, an estimated $9.55K sold.
Based on aggregated 13F filings for Q4 2024.